On Wednesday, TherapeuticsMD Inc (NYSEMKT:TXMD)’s shares declined -5.92% to $6.04.
TherapeuticsMD Inc (TXMD) declared its first quarter financial results for the period ended March 31, 2015.
First quarter and recent corporate developments
Net revenue raised to about $4.5 million for the quarter ended March 31, 2015, contrast with about $2.8 million for the quarter ended March 31, 2014.
Net loss was about $20.9 million for the quarter ended March 31, 2015, contrast with about $9.2 million for the quarter ended March 31, 2014, reflecting raised costs associated with the company’s continued enrollment of patients in two phase 3 clinical trials for its novel hormone therapy product candidates.
TherapeuticsMD, Inc. operates as a women’s health care product company. The company manufactures and distributes prescription and over-the-counter product lines, counting prenatal vitamins, iron supplements, vitamin D supplements, and natural menopause relief products under the vitaMedMD brand, in addition to duplicate formulations of its prescription prenatal vitamins products under the BocaGreenMD Prena1 name.
News Corp (NASDAQ:NWSA)’s shares dropped -6.43% to $14.99.
News Corp (NWSA) stated third quarter Total Segment EBITDA of $163 million, a 7% decline as contrast to $175 million in the preceding year. These results comprise $15 million and $20 million in fees and costs – net of indemnification – related to the U.K. Newspaper Matters in the three months ended March 31, 2015 and 2014, respectively. Declines at the News and Information Services segment, counting higher legal costs at News America Marketing, negative foreign currency fluctuations and raised stock-based compensation expense resulting from the acquisition of Move were partially offset by lower expenses at Amplify and raised revenues in the Book Publishing segment due to the inclusion of Harlequin results. Adjusted Total Segment EBITDA declined 1% contrast to the preceding year.
Net income accessible to News Corporation stockholders was $23 million as contrast to $48 million in the preceding year, due to lower Total Segment EBITDA in addition to a higher effective tax rate, lower equity earnings of associates, and lower interest income.
News Corporation, a media and information services company, focuses on creating and distributing authoritative and engaging content to consumers and businesses worldwide. The company operates through News and Information Services, Cable Network Programming, Digital Real Estate Services, Book Publishing, and Digital Education segments.
At the end of Wednesday’s trade, Theravance Inc (NASDAQ:THRX)‘s shares dipped -6.27% to $15.56.
Theravance Inc (THRX) stated financial results for the first quarter ended March 31, 2015. Royalties earned on net sales of RELVAR®/BREO® ELLIPTA® and ANORO® ELLIPTA® from Glaxo Group Limited (GSK) during the first quarter 2015 were $10.1 million, and income from operations raised to $0.7 million, contrast to $0.1 million in the fourth quarter of 2014. Adjusted EBITDA for the first quarter of 2015 was $6.2 million. Net loss for the first quarter 2015 was $10.7 million or $0.09 per share. Cash and cash equivalents, short-term investments, and marketable securities totaled $255.1 million as of March 31, 2015.
Theravance also declared that the company’s Board of Directors has declared a $0.25 per share cash dividend to be paid on June 30, 2015 to stockholders of record as of the close of business on June 12, 2015.
Theravance, Inc., a royalty administration company, is focused on developing respiratory products. It receives royalty revenues RELVAR/BREO ELLIPTA (fluticasone furoate/vilanterol, FF/VI), ANORO ELLIPTA (umeclidinium bromide/vilanterol, UMEC/VI), and VI monotherapy through the Long-Acting Beta2 Agonist partnershipagreement and the planned alliance agreement with Glaxo Group Limited (GSK).
3D Systems Corporation (NYSE:DDD), ended its Wednesday’s trading session with -5.41% loss, and closed at $22.90.
3D Systems Corporation (DDD) declared its financial results for the first quarter of 2015.
For the quarter ended March 31, 2015, the company stated revenue of $160.7 million, an enhance of 9% over the comparable quarter in 2014, or a 17% enhance on a constant currency basis. The company stated a GAAP loss of $0.12 per share and non-GAAP earnings of $0.05 per share.
The company believes that negative currency headwinds and demand weakness attributed to several other macroeconomic factors resulted in lower than predictable purchases of its 3D printers and materials by aerospace, automotive and healthcare customers during the quarter. Furthermore, the company stated that certain metal and nylon applications and performance issues delayed its ability to sell additional printers during the first quarter of 2015. Combined, these factors reduced sales of the company’s design and manufacturing printers and materials and resulted in a decline in organic revenue of 7% contrast to total revenue in the first quarter of 2014.
3D Systems Corporation, through its auxiliaries, operates as a provider of 3D printing centric design-to-manufacturing solutions in the Americas, Germany, and the Asia-Pacific, in addition to other European, the Middle East, and African countries.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
